Fig. 1.

Schematic overview of OVA-specific cytotoxic T lymphocyte (OVA-CTL)-based tumor imaging and therapy. The OVA-CTLs were metabolically labeled with ⁶⁴Cu, and injected into tumor-bearing mice for small-animal PET imaging. For the therapy studies, the OVA-CTLs were injected into tumor-bearing mice with the combination of a PLGA-FAKi nanodrug (FAKi focal adhesion kinase inhibitor)